Treatment with the arginase inhibitor N(omega)-hydroxy-nor-L-arginine improves vascular function and lowers blood pressure in adult spontaneously hypertensive rat

J Hypertens. 2008 Jun;26(6):1110-8. doi: 10.1097/HJH.0b013e3282fcc357.

Abstract

Objective: High vascular arginase activity and subsequent reduction in vascular nitric oxide production were recently reported in animal models of hypertension. The present study investigated the effects of in-vivo arginase inhibition on blood pressure and vascular function in adult spontaneously hypertensive rats.

Methods: Ten-week-old spontaneously hypertensive rats and normotensive age-matched Wistar-Kyoto rats were treated with or without the selective arginase inhibitor N-hydroxy-nor-L-arginine for 3 weeks (10 or 40 mg/kg per day, intraperitoneally). Systolic blood pressure and cardiac rate were measured before and during treatment. Flow and pressure-dependent reactivity as well as remodeling of mesenteric arteries, acetylcholine-dependent vasodilation of aortic rings, cardiac hypertrophy, arginase activity and nitric oxide production were investigated in 13-week-old spontaneously hypertensive rats.

Results: In spontaneously hypertensive rats, N-hydroxy-nor-L-arginine treatment decreased arginase activity (30-40%), reduced blood pressure ( approximately 35 mmHg) and improved the reactivity of mesenteric vessels. However, vascular and cardiac remodeling was not different between treated and untreated spontaneously hypertensive rats. In Wistar-Kyoto rats, N-hydroxy-nor-L-arginine did not affect blood pressure. Finally, arginase inhibition was associated with increased nitric oxide production. Consistent with this, the response of aortic rings to acetylcholine was fully restored by N-hydroxy-nor-L-arginine, and the nitric oxide synthase inhibitor NG-nitro-L-arginine methyl ester significantly reduced the effect of N-hydroxy-nor-L-arginine on flow-dependent vasodilation.

Conclusion: Pharmacological inhibition of arginase in adult spontaneously hypertensive rats decreases blood pressure and improves the reactivity of resistance vessels. These data represent in-vivo argument in favor of selective arginase inhibition as a new therapeutic strategy against hypertension.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Aorta, Thoracic / drug effects
  • Aorta, Thoracic / physiopathology
  • Arginase / antagonists & inhibitors*
  • Arginase / metabolism
  • Arginine / analogs & derivatives*
  • Arginine / pharmacology
  • Arginine / therapeutic use
  • Blood Glucose / metabolism
  • Blood Pressure / drug effects*
  • Body Weight / drug effects
  • Endothelium, Vascular / drug effects
  • Endothelium, Vascular / physiopathology
  • Heart Rate / drug effects
  • Hypertension / drug therapy*
  • Hypertension / physiopathology
  • In Vitro Techniques
  • Isoenzymes / metabolism
  • Kidney / enzymology
  • Liver / enzymology
  • Male
  • Mesenteric Arteries / drug effects*
  • Mesenteric Arteries / physiopathology
  • Nitric Oxide / metabolism
  • Rats
  • Rats, Inbred SHR
  • Rats, Inbred WKY
  • Urea / blood
  • Vasoconstriction / drug effects

Substances

  • Blood Glucose
  • Isoenzymes
  • N(omega)-hydroxynorarginine
  • Nitric Oxide
  • Urea
  • Arginine
  • Arginase